One-of-a-kind technology enhances care for patients across surgical, perioperative and emergency care environments Agiliti, a leading manufacturer and provider of medical device solutions to the U.S.
Enhanced Recovery After Surgery (ERAS) programs have changed perioperative care in gastrointestinal (GI) and hepatopancreatobiliary (HPB) oncology by ...
Explore the fun and educational Bing Homepage Quiz. Learn how to play, where to find it, and tips to improve your score while enjoying Bing’s stunning daily backgrounds.
Morningstar: Agiliti Introduces Capillaire™ — Low-Profile Alternating Pressure Overlay Clinically Proven to Prevent Perioperative Pressure Injuries
Agiliti Introduces Capillaire™ — Low-Profile Alternating Pressure Overlay Clinically Proven to Prevent Perioperative Pressure Injuries
Frontiers: Enhanced Recovery and Perioperative Optimization in Gastrointestinal and Hepatopancreatobiliary Cancer Surgery
Becker’s has compiled a list of perioperative service leaders at leading hospitals and health systems. These leaders are responsible for optimizing operating room productivity, boosting surgical team ...
Becker's Hospital Review: Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
ascopubs.org: Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
goskagit.com: U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility